Datapoint: Latest Patent Ruling Protects Imbruvica Until 2032

AbbVie and Johnson & Johnson last week won a patent lawsuit in favor of their oncology drug Imbruvica, which now won’t see generic competition until at least 2032. The legal battle against Alvogen and Natco Pharma began in 2019. Imbruvica, which launched in 2014, is approved to treat several cancers, including chronic lymphocytic leukemia, mantle cell lymphoma and non-Hodgkin lymphoma. Under the pharmacy benefit, Imbruvica holds covered or better status for 71% of all insured lives.

SOURCE: MMIT Analytics, as of 9/1/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 21

Datapoint: Cigna, HelloFresh Partner on Meal Kit Benefits

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 20

Datapoint: SCAN, CareOregon Nix Merger Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 15

Datapoint: AbbVie Completes ImmunoGen Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today